Podcast Episodes
Back to Search
Lilly’s Q3 Miss, Novo’s MASH Win, CAR T’s Autoimmune Pivot, More
Last week, Eli Lilly suffered a rare third-quarter earnings miss as diabetes and obesity drugs Mounjaro and Zepbound fell short of Wall Street expect…
1 year, 8 months ago
Pfizer’s Q3 Earnings Win, Deals Galore, Countdown to Election, More
Earnings heat up as Pfizer got a much-needed Q3 beat amidst criticism from activist investor Starboard Value. Novartis and Sanofi are among others th…
1 year, 8 months ago
Steady But Slow: Future Outlook for Investment
In this episode, we’re talking money.
The guests in this discussion recognize that the economic climate has been different (and more chaotic) in last…
1 year, 8 months ago
Trodelvy’s Bladder Cancer Withdrawal, Sage Therapeutics Layoffs, Sanofi’s Radiopharma Investment, More
Last week, Gilead withdrew Trodelvy in bladder cancer after the antibody-drug conjugate failed to meet the primary endpoint in a confirmatory study. …
1 year, 8 months ago
Q3 Earnings Kick Off With J&J, Bluebird in Tough Spot, Novo-Catalent Deal Under Fire, More
It’s that time again: earnings season. Q3 calls started out with a bit of a snore from J&J, which did beat analyst expectations but announced no big …
1 year, 8 months ago
How AI Could Ease Tension in Clinical Trials
Designating something "safe" in this industry means acceptable risk. AI can help us improve acceptable risks if it is used appropriately. However, in…
1 year, 9 months ago
BioSpace at Meeting on the Mesa, WuXi Considers Selling U.S. Facilities, Big Pharma Layoffs, More
The cell and gene therapy sector may be on the road to recovery after being met with investment headwinds following the highs seen during the pandemi…
1 year, 9 months ago
BMS’ Schizophrenia Approval, Pfizer’s Sudden Sickle Cell Withdrawal and Roche’s Pharma Day
Bristol Myers Squibb notched one of this year’s biggest approvals as the FDA greenlit Cobenfy, formerly KarXT, as the first novel treatment for sch…
1 year, 9 months ago
AI Return on Investment: Just Because We Can, Should We?
Globalization, return on investment, diverse data sets undiscovered: this episode continues the exploration of AI. As we see the industry level out A…
1 year, 9 months ago
Novo Grilled By Senate, PhRMA’s IRA Win and BMS’ KarXT Awaits Approval
Novo Nordisk CEO Lars Fruergaard Jørgensen testified Tuesday in front of Sen. Bernie Sanders’ Senate health committee regarding the prices of Ozempic…
1 year, 9 months ago